Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Tries Out New Selling Strategy With Yervoy Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Company details "new customer model" with an integrated reimbursement and medical support team that is being rolled out for the ipilimumab launch.

You may also be interested in...



Yervoy Off to Strong Start, Says BMS' Tony Hooper

The launch of Bristol's metastatic melanoma therapy is off to a strong start, but uncertainties linger, including whether the drug will compete with Roche's BRAF inhibitor.

Yervoy Off to Strong Start, Says BMS' Tony Hooper

The launch of Bristol's metastatic melanoma therapy is off to a strong start, but uncertainties linger, including whether the drug will compete with Roche's BRAF inhibitor.

As Yervoy Launch Nears, Pricing Of Maintenance Therapy Remains A Key Question

FDA’s approval of Bristol-Myers Squibb’s Yervoy (ipilimumab) for unresectable or metastatic melanoma March 25 grabbed attention for several reasons – the monoclonal antibody is the first new treatment approved for advanced melanoma in 13 years and the first ever to demonstrate a survival benefit.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel